Ubiquitin and the molecular pathology of neurodegenerative diseases

Advances in Experimental Medicine and Biology

Volumn 487, Issue , 2001, Pages 169-186

  Lowe, James ^a   Mayer, John ^a   Landon, Michael ^a   Layfield, Robert ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTALLIN; TAU PROTEIN; UBIQUITIN;

CELL INCLUSION; CONFERENCE PAPER; CYTOSOL; DEGENERATIVE DISEASE; DEMENTIA; FRONTOTEMPORAL DEMENTIA; IMMUNOHISTOCHEMISTRY; LEWY BODY; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIBODIES; APHASIA; DEMENTIA; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; INTERMEDIATE FILAMENT PROTEINS; MOTOR NEURON DISEASE; NEURODEGENERATIVE DISEASES; TAU PROTEINS; UBIQUITINS;

EID: 0034982171     PISSN: 00652598     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-1-4615-1249-3_14     Document Type: Article

References (144)

1. Ubiquitin-mediated proteolysis: Biological regulation via destruction
2. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
3. Modes of regulation of ubiquitin-mediated protein degradation
4. Deubiquitinating enzymes: Their diversity and emerging roles
5. Ubiquitin and the molecular pathology of human disease
6. The ligation systems for ubiquitin and ubiquitin-like proteins
7. Ubiquitin-like proteins: New wines in new bottles
8. Ubiquitin in health and disease
9. Establishing a pathological diagnosis in degenerative dementias
10. Stains for the differential diagnosis of degenerative dementias
11. The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates
12. Production and characterization of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins
13. Tumour necrosis factor enhances induction by beta-interferon of a ubiquitin cross-reactive protein
14. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins
15. Immunohistochemical localization of ubiquitin cross-reactive protein in human tissues
16. The structure of the human gene encoding protein gene product 9.5 (PGP9.5), a neuron-specific ubiquitin C-terminal hydrolase
17. Protein gene product (PGP) 9.5 in diagnostic (neuro-) oncology. An immunomorphological study
18. Protein gene product (PGP) 9.5 as a reliable marker in primitive neuroectodermal tumours-An immunohistochemical study of 21 childhood cases
19. PGP 9.5-A new marker for vertebrate neurons and neuroendocrine cells
20. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase
21. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies
22. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases
23. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
24. Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects
25. The "normal" brain. "Abnormal" ubiquitinilated deposits highlight an age-related protein change
26. Age-related ubiquitin deposits in dystrophic neurites: An immunoelectron microscopic study
27. Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease
28. Senile plaque neurites in Alzheimer's disease accumulate amyloid precursor protein
29. Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques
30. Identification of normal and pathological aging in prospectively studied nondemented elderly humans
31. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease
32. Two types of dystrophic neurites in senile plaques of Alzheimer disease and elderly non-demented cases
33. Two distinct ubiquitin immunoreactive senile plaques in Alzheimer's disease: Relationship with the intellectual status in 29 cases
34. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro
35. Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis
36. Alzheimer's disease brain-derived ubiquitin has amyloid-enhancing factor activity: Behavior of ubiquitin during accelerated amyloidogenesis
37. Amyloid enhancing factor activity is associated with ubiquitin
38. Ubiquitin: Its potential significance in murine AA amyloidogenesis
39. Ubiquitin immunocytochemistry in human spongiform encephalopathies
40. Dystrophic neurites around amyloid plaques of human patients with Gerstmann-Straussler-Scheinker disease contain ubiquitinated inclusions
41. Lysosomes as key organelles in the pathogenesis of prion encephalopathies
42. Immunoreactivity to ubiquitin-protein conjugates is present early in the disease process in the brains of scrapie-infected mice
43. Ubiquitin conjugate immunoreactivity in the brains of scrapie infected mice
44. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease
45. Ubiquitin: New insights into chronic degenerative diseases
46. Ubiquitin, cell stress and diseases of the nervous system
47. Ubiquitin in neurodegenerative diseases
48. AlphaB crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease
49. Selective presence of ubiquitin in intracellular inclusions
50. Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleinopathies
51. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson's disease
52. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia
53. Lessons from keratin 18 knockout mice: Formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates
54. Mutation R120G in alphaB-crystallin, which is linked to a desmin-related myopathy, results in an irregular structure and defective chaperone-like function
55. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene
56. The genetics of disorders with synuclein pathology and parkinsonism
57. The ubiquitin pathway in Parkinson's disease
58. A missense mutation in the alpha-B-crystallin chaperone gene causes a desmin-related myopathy
59. Intermediate filament-ubiquitin diseases: Implications for cell sanitization
60. Aggresomes: A cellular response to misfolded proteins
61. Ubiquitin-protein conjugates in Alzheimer's lesions
62. Ubiquitin is a component of paired helical filaments in Alzheimer's disease
63. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains
64. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease
65. Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton
66. Lack of ubiquitin immunoreactivities at both ends of neuropil threads. Possible bidirectional growth of neuropil threads
67. Posttranslational modifications of tau in paired helical filaments
68. Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies
69. Immunocytochemical and ultrastructural studies of Pick's disease
70. Multiple system atrophy: A sporadic synucleinopathy
71. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)
72. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy
73. Ubiquitinated alphaB-crystallin in glial cytoplasmic inclusions from the brain of a patient with multiple system atrophy
74. Transgenic mice in the study of polyglutamine repeat expansion diseases
75. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
76. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
77. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
78. Nuclear inclusions in spinocerebellar ataxia type 1
79. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset
80. Hereditary dentatorubral-pallidoluysian atrophy: Detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain
81. Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: Triple-labeling immunofluorescent study
82. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients
83. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein
84. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro
85. Are there multiple pathways in the pathogenesis of Huntington's disease?
86. Infantile multiple system atrophy with cytoplasmic and intranuclear glioneuronal inclusions
87. Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions
88. Neuronal intranuclear hyaline inclusion disease with polyglutamine-immunoreactive inclusions
89. Amyotrophic lateral sclerosis: Current issues in classification, pathogenesis and molecular pathology
90. Ubiquitin deposits in anterior horn cells in motor neurone disease
91. New pathological findings in amyotrophic lateral sclerosis
92. Inclusion bodies in motor cortex and brainstem of patients with motor neurone disease are detected by immunocytochemical localisation of ubiquitin
93. A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin
94. Ubiquitinated filamentous inclusions in spinal cord of patients with motor neuron disease
95. Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis
96. Ubiquitin in motor neuron disease: Study at the light and electron microscope
97. Involvement of the amygdala, dentate and hippocampus in motor neuron disease
98. Histochemical and immunocytochemical study of ubiquitinated neuronal inclusions in amyotrophic lateral sclerosis
99. Hereditary dentatorubral-pallidoluysian atrophy: Ubiquitinated filamentous inclusions in the cerebellar dentate nucleus neurons
100. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement
101. Tau, ubiquitin, and alphaB-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia
102. Skein-like inclusions in the neostriatum from a case of amyotrophic lateral sclerosis with dementia
103. Dementia of frontal type and dementias with subcortical gliosis
104. Motor neurone disease-inclusion dementia
105. The new neuropathology of degenerative frontotemporal dementias
106. Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions
107. Ubiquitin-related cytoskeletal abnormality in frontotemporal dementia: Immunohistochemical and immunoelectron microscope studies
108. Semantic dementia with ubiquitin-positive tau-negative inclusion bodies
109. Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration
110. Primary progressive aphasia
111. Rapidly progressive aphasia and motor neuron disease: A clinical, radiological, and pathological study of an autopsy case with circumscribed lobar atrophy
112. Motor neuron disease with pallido-luysio-nigral atrophy
113. Frontal lobe degeneration: Novel ubiquitin-immunoreactive neurites within frontotemporal cortex
114. Expression of ubiquitin-like immunoreactivity in axons after compression trauma to rat spinal cord
115. Ubiquitin marks the reactive swellings of diffuse axonal injury
116. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD
117. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease
118. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease
119. Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies
120. Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: A pathological correlate of dementia?
121. The cortical neuritic pathology of Huntington's disease
122. Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden-Spatz disease and infantile neuroaxonal dystrophy
123. Lewy body in neurodegeneration with brain iron accumulation type I is immunoreactive for alpha-synuclein
124. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury
125. Degradation of alpha-synuclein by proteasome
126. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA 1 mice
127. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA 1
128. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
129. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
130. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
131. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease
132. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease
133. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
134. Neuropathology of gracile axonal dystrophy (GAD) mouse. An animal model of central distal axonopathy in primary sensory neurons
135. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice
136. Gracile axonal dystrophy (GAD), a new neurological mutant in the mouse
137. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell
138. Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshiff mutant ubiquitin-B protein
139. Molecular misreading. A new type of transcript mutation in gerontology
140. Molecular misreading of genes in Down syndrome as a model for the Alzheimer type of neurodegeneration
141. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease
142. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates
143. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2)